EVT.DE - Evotec AG

XETRA - XETRA Delayed Price. Currency in EUR
20.54
+0.08 (+0.39%)
As of 10:35AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close20.46
Open20.53
Bid20.54 x 105300
Ask20.58 x 169300
Day's Range20.47 - 20.84
52 Week Range11.52 - 22.50
Volume184,392
Avg. Volume1,137,775
Market Cap3.025B
Beta0.81
PE Ratio (TTM)160.47
EPS (TTM)0.13
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.46
  • ACCESSWIRE6 days ago

    Evotec Partner Haplogen Enters Into Collaboration With Bayer

    HAMBURG, GERMANY / ACCESSWIRE / August 14, 2018 / Evotec AG (EVT.F) (EVT.DE) (OTC PINK:EVTCY), (TecDAX, ISIN: DE0005664809) announced today that Haplogen GmbH ("Haplogen"), a Vienna-based biotechnology company and collaboration partner of Evotec, has entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease ("COPD"). Since Haplogen and Evotec began collaborating in 2012, collectively, they built a robust portfolio of pulmonary therapeutic programmes based on the industry-leading drug discovery platforms and know-how of both companies.

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of EVT.DE earnings conference call or presentation 9-Aug-18 12:00pm GMT

    Half Year 2018 Evotec AG Earnings Call

  • ACCESSWIRE11 days ago

    Evotec AG Reports First Half-Year 2018 Results And Corporate Updates

    - SIGNIFICANT GROWTH OF EVT EXECUTE AND EVT INNOVATE - 67% INCREASE IN GROUP REVENUES, 47% INCREASE IN ADJUSTED GROUP EBITDA - REPAYMENT OF 50% (EUR 70 M) OF APTUIT ACQUSITION LOAN WITHIN ONE YEAR - WEBCAST ...

  • With An ROE Of 6.00%, Can Evotec AG (ETR:EVT) Catch Up To The Industry?
    Simply Wall St.12 days ago

    With An ROE Of 6.00%, Can Evotec AG (ETR:EVT) Catch Up To The Industry?

    I am writing today to help inform people who are new to the stock market and want to learn about Return on Equity using a real-life example. Evotec AG’s (ETR:EVT)Read More...

  • ACCESSWIRE18 days ago

    Evotec AG to Report First Half-Year 2018 Results on 09 August 2018

    HAMBURG, GERMANY / ACCESSWIRE / August 2, 2018 / Evotec AG (FSE: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for the first half of 2018 on Thursday, 09 August 2018. The Company is ...

  • ACCESSWIRE20 days ago

    Evotec Repays 50% Of EUR 140 M Acquisition Loan

    STRONG OPERATIONAL CASHFLOW FACILITATES REPAYMENT OF EUR 70 M WITHIN THE FIRST YEAR OF THE LOAN TERM EUR 140 M LOAN WAS TAKEN TO EXPAND EVOTEC'S VALUE CHAIN WITH APTUIT IN AUGUST 2017 HAMBURG, GERMANY ...

  • ACCESSWIRElast month

    Evotec Receives Milestone Payment For Start Of Phase II Trial In Its Multi-Target Alliance With Bayer

    HAMBURG, GERMANY / ACCESSWIRE / July 19, 2018 / Evotec AG (EVT.DE), (EVT.DE) (ISIN:DE0005664809) announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting in a payment of EUR 4 m to Evotec. Chronic cough is a major global health burden and has a significant impact on the quality of life of millions of people. Currently, no therapies are approved for the treatment of chronic cough.

  • Updates on the Sanofi-Evotec Diabetes Business Collaboration
    Market Realist2 months ago

    Updates on the Sanofi-Evotec Diabetes Business Collaboration

    On June 25, Sanofi and Evotec reached the second milestone of the diabetes business alliance they entered into in August 2015, with a payment of 3 million euros from Sanofi to Evotec after the latter had met “pre-agreed critical success criteria for a potential manufacturing process” for generating human induced pluripotent stem cell-derived beta cells. The deal aims to extend Evotec’s metabolic disease and stem cell-based drug discovery programs and enhance Sanofi’s extensive diabetes research and development pipeline. According to the agreement, Evotec is eligible to receive as much as 300 million euros in milestone-based payments from Sanofi as well as royalties and research payments. To date, the company has received 9 million euros in upfront milestone-based payments and research funding from Sanofi.

  • Sanofi Signs Over Anti-Infectives Unit to Evotec
    Market Realist2 months ago

    Sanofi Signs Over Anti-Infectives Unit to Evotec

    On June 15, Sanofi (SNY) and Evotec, a Germany-based drug discovery and development company, signed an agreement to transfer Sanofi’s anti-infectives unit to Evotec for $70 million. Sanofi will also transfer 100 employees to Evotec and licenses for more than ten infectious disease R&D (research and development) pipeline assets.

  • ACCESSWIRE2 months ago

    Evotec Confirm Closing Of Transaction With Sanofi To Accelerate Infectious Disease Research And Development

    HAMBURG, GERMANY / ACCESSWIRE / July 3, 2018 / Evotec AG (EVT.DE), (EVT.DE) (ISIN:DE0005664809) today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi's infectious disease unit including licensing-in the majority of Sanofi's infectious disease research portfolio, has been successfully closed with effect from 01 July 2018. The transaction will result in a EUR 60 m upfront cash payment and a guaranteed financial commitment from Sanofi to Evotec for five years. Evotec will accelerate the infectious disease research pipeline development and initiate new open innovation R&D initiatives in anti-infectives.

  • ACCESSWIRE2 months ago

    Evotec Achieves Second Milestone in Diabetes Alliance With Sanofi

    COMPANIES ARE AT THE FOREFRONT OF BETA CELL REPLACEMENT THERAPEUTIC RESEARCH FOR DIABETES EVOTEC RECEIVES EUR 3 MILLION PAYMENT FROM SANOFI MILESTONE FURTHER DEMONSTRATES ADVANCEMENT OF EVT INNOVATE INITIATIVE ...

  • Is It The Right Time To Buy Evotec AG (ETR:EVT)?
    Simply Wall St.2 months ago

    Is It The Right Time To Buy Evotec AG (ETR:EVT)?

    Evotec AG (ETR:EVT), a life sciences company based in Germany, received a lot of attention from a substantial price increase on the XTRA over the last few months. As aRead More...

  • ACCESSWIRE2 months ago

    Resolutions of the Annual General Meeting 2018 of Evotec AG

    HAMBURG, GERMANY / ACCESSWIRE / June 20, 2018 / Evotec AG (FSE: EVT, XETRA: EVT) (ISIN:DE0005664809) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting 2018 with the required majorities. The strategy and its execution by the members of the Management Board and the Supervisory Board for the fiscal year 2017 were supported and approved.

  • ACCESSWIRE2 months ago

    Evotec And Sanofi Sign Definitive Agreement To Combat Infectious Diseases

    HAMBURG, GERMANY / ACCESSWIRE / June 18, 2018 / Evotec AG (EVT.F) (EVT.DE) (ISIN:DE0005664809) today announced having signed a transaction agreement with Sanofi to integrate Sanofi's infectious disease unit into its organisation.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of EVT.DE earnings conference call or presentation 9-May-18 12:00pm GMT

    Q1 2018 Evotec AG Earnings Call

  • Benzinga3 months ago

    Celgene Forges Oncology Partnership With Germany's Evotec

    Celgene Corporation (NASDAQ: CELG ) — which is recently very much in the news, although for dubious reasons — has struck a partnership with Germany's Evotec AG (ADR) (OTC: EVTCY ), which partners with ...

  • Does Evotec AG’s (ETR:EVT) -11.89% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.3 months ago

    Does Evotec AG’s (ETR:EVT) -11.89% Earnings Drop Reflect A Longer Term Trend?

    After looking at Evotec AG’s (XTRA:EVT) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...

  • Evotec AG (ETR:EVT): What Can We Expect From This High Growth Stock?
    Simply Wall St.4 months ago

    Evotec AG (ETR:EVT): What Can We Expect From This High Growth Stock?

    The latest earnings announcement Evotec AG’s (XTRA:EVT) released in December 2017 confirmed that the business endured a immense headwind with earnings declining by -11.89%. Below is a brief commentary onRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of EVT.DE earnings conference call or presentation 28-Mar-18 12:00pm GMT

    Q4 2017 Evotec AG Earnings Call

  • What Does Evotec AG’s (ETR:EVT) Share Price Indicate?
    Simply Wall St.5 months ago

    What Does Evotec AG’s (ETR:EVT) Share Price Indicate?

    Evotec AG (XTRA:EVT), a life sciences company based in Germany, saw a significant share price rise of over 20% in the past couple of months on the XTRA. With manyRead More...

  • What You Must Know About Evotec AG’s (ETR:EVT) Return on Equity
    Simply Wall St.5 months ago

    What You Must Know About Evotec AG’s (ETR:EVT) Return on Equity

    Evotec AG’s (XTRA:EVT) most recent return on equity was a substandard 8.96% relative to its industry performance of 9.32% over the past year. EVT’s results could indicate a relatively inefficientRead More...

  • Capital Cube8 months ago

    ETFs with exposure to Evotec AG : December 29, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Evotec AG Here are 5 ETFs with the largest exposure to EVT-DE. Comparing the performance and risk of Evotec AG with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents9 months ago

    Edited Transcript of EVT.DE earnings conference call or presentation 8-Nov-17 1:00pm GMT

    Q3 2017 Evotec AG Earnings Call

  • Capital Cube10 months ago

    ETFs with exposure to Evotec AG : October 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Evotec AG Here are 5 ETFs with the largest exposure to EVT-DE. Comparing the performance and risk of Evotec AG with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)